The following video is part of our "Motley Fool Conversations" series, in which analyst Jim Mueller and analyst Jason Moser discuss topics around the investing world.
Dendreon (NAS: DNDN) has had a volatile history as a stock as it developed and then brought to market its prostate cancer drug, Provenge. Today, Motley Fool Stock Advisor analysts Jim Mueller and Jason Moser discuss why today might finally be the time to invest in this biotech company.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time thisarticle was published Jason Moser has no positions in the stocks mentioned above. Jim Mueller owns shares of Johnson & Johnson and has options on Dendreon. The Motley Fool owns shares of Dendreon and Johnson & Johnson.Motley Fool newsletter services recommendJohnson & Johnson. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.